Share on LinkedInShare on LinkedIn

ARTICLE · 30 NOVEMBER 2023

FCA Dismisses Appeal, Patent Not Listable Against STELARA SNDS

As previously reported, the Federal Court (FC) dismissed Janssen's application for judicial review of the decision of the Office of Submissions and Intellectual Property (OSIP) refusing to list...

CanadaIntellectual Property

As previously reported, the Federal Court (FC) dismissed Janssen's application for judicial review of the decision of the Office of Submissions and Intellectual Property (OSIP) refusing to list Canadian Patent No. 3,113,837 on the Patent Register with respect to two supplementary new drug submissions (SNDSs) for Janssen's STELARA (ustekinumab). On November 21, 2023, the Federal Court of Appeal (FCA) dismissed Janssen's appeal: Janssen Inc v Canada (Health), 2023 FCA 229.

Janssen appealed the decision in respect of SNDS 224739 (739 submission). OSIP had determined that:

  1. the patent list for another submission that was submitted within the 30-day deadline did not relate to the 739 submission, and;

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

See more popular content from